References
- Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S.,
Unwin, N., … & IDF Diabetes Atlas Committee. (2019). Global and
regional diabetes prevalence estimates for 2019 and projections for
2030 and 2045: Results from the International Diabetes Federation
Diabetes Atlas. Diabetes research and clinical practice, 157, 107843.
- Maitra A, Abbas AK. Endocrine system. In: Kumar V, Fausto N, Abbas AK
(eds). Robbins and Cotran Pathologic basis of disease (7th ed) 2005.
Philadelphia, Saunders; 1156-1226.
- Neumiller, Joshua J., and Guillermo E. Umpierrez. ”2018 Standards of
Care Update: Pharmacologic Approaches to Glycemic Management in People
with Type 2 Diabetes.” Diabetes Spectrum 31.3 (2018): 254-260.
- American Diabetes Association. ”9. Pharmacologic Approaches to
Glycemic Treatment: Standards of Medical Care in Diabetes-2020.”
Diabetes Care 43.Suppl 1 (2020): S98.
- Dash, Ranjeet Prasad, R. Jayachandra Babu, and Nuggehally R. Srinivas.
”Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin,
remogliflozin and ertugliflozin: an overview.” Xenobiotica 47.11
(2017): 1015-1026.
- Garcia-Ropero, Alvaro, Juan J. Badimon, and Carlos G. Santos-Gallego.
”The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for
type 2 diabetes mellitus: the latest developments.” Expert Opinion on
Drug Metabolism & Toxicology 14.12 (2018): 1287-1302.
- American Diabetes Association. ”9. Pharmacologic approaches to
glycemic treatment: Standards of Medical Care in Diabetes—2021.”
Diabetes Care 44.Supplement 1 (2021): S111-S124.
- Gorboulev V, Schurmann A, Vallon V et al (2012) Na+-D-glucose
cotransporter SGLT1 is pivotal for intestinal glucose absorption and
glucose-dependent incretin secretion. Diabetes 61:187–196
- Song P, Onishi A, Koepsell H, Vallon V (2016) Sodium glucose
cotransporter SGLT1 as a therapeutic target in diabetes mellitus.
Expert Opin Ther Targets 20:1109–1125
- Rieg, Timo, and Volker Vallon. ”Development of SGLT1 and SGLT2
inhibitors.” Diabetologia 61.10 (2018): 2079-2086.
- Wiviott, Stephen D., et al. ”Dapagliflozin and cardiovascular outcomes
in type 2 diabetes.” New England Journal of Medicine 380.4 (2019):
347-357.
- Hsia, Daniel S., Owen Grove, and William T. Cefalu. ”An update on
SGLT2 inhibitors for the treatment of diabetes mellitus.” Current
opinion in endocrinology, diabetes, and obesity 24.1 (2017): 73.
- Nespoux, Josselin, and Volker Vallon. ”SGLT2 inhibition and kidney
protection.” Clinical Science 132.12 (2018): 1329-1339.
- Zelniker, Thomas A., et al. ”SGLT2 inhibitors for primary and
secondary prevention of cardiovascular and renal outcomes in type 2
diabetes: a systematic review and meta-analysis of cardiovascular
outcome trials.” The Lancet 393.10166 (2019): 31-39.
- Garcia-Ropero, Alvaro, Juan J. Badimon, and Carlos G. Santos-Gallego.
”The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for
type 2 diabetes mellitus: the latest developments.” Expert Opinion on
Drug Metabolism & Toxicology 14.12 (2018): 1287-1302.
- Goldenberg, Ronald M., et al. ”SGLT2 inhibitor–associated diabetic
ketoacidosis: clinical review and recommendations for prevention and
diagnosis.” Clinical Therapeutics 38.12 (2016): 2654-2664.
- Kim, Ju-Hyun, et al. ”In Vitro Metabolism of DWP16001, a Novel
Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal
Hepatocytes.” Pharmaceutics 12.9 (2020): 865.
- Choi, Min-Koo, et al. ”Comparative Pharmacokinetics and
Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor,
DWP16001, with Dapagliflozin and Ipragliflozin.” Pharmaceutics 12.3
(2020): 268.
- Rieg, Timo, et al. ”Increase in SGLT1-mediated transport explains
renal glucose reabsorption during genetic and pharmacological SGLT2
inhibition in euglycemia.” American Journal of Physiology-Renal
Physiology 306.2 (2014): F188-F193.
- Lu, Yasong, et al. ”Use of systems pharmacology modeling to elucidate
the operating characteristics of SGLT1 and SGLT2 in renal glucose
reabsorption in humans.” Frontiers in pharmacology 5 (2014): 274.
- Chen, Xia, et al. ”Pharmacokinetics, pharmacodynamics, and safety of
single-dose canagliflozin in healthy Chinese subjects.” Clinical
therapeutics 37.7 (2015): 1483-1492.
- Komoroski, B., et al. ”Dapagliflozin, a novel SGLT2 inhibitor, induces
dose‐dependent glucosuria in healthy subjects.” Clinical Pharmacology
& Therapeutics 85.5 (2009): 520-526.
- Sha, Sue, et al. ”Pharmacodynamic effects of canagliflozin, a sodium
glucose co-transporter 2 inhibitor, from a randomized study in
patients with type 2 diabetes.” PloS one 9.8 (2014): e105638.
- Kasichayanula, S., et al. ”Pharmacokinetics and pharmacodynamics of
dapagliflozin, a novel selective inhibitor of sodium–glucose
co‐transporter type 2, in Japanese subjects without and with type 2
diabetes mellitus.” Diabetes, Obesity and Metabolism 13.4 (2011):
357-365.
- Gilbert, Richard E., and Kevin E. Thorpe. ”Acute kidney injury with
sodium‐glucose co‐transporter‐2 inhibitors: A meta‐analysis of
cardiovascular outcome trials.” Diabetes, Obesity and Metabolism 21.8
(2019): 1996-2000.
- Sugiyama, Seigo, et al. ”Impact of dapagliflozin therapy on renal
protection and kidney morphology in patients with uncontrolled type 2
diabetes mellitus.” Journal of clinical medicine research 10.6 (2018):
466.
- Satirapoj, Bancha, Pattharamon Korkiatpitak, and Ouppatham Supasyndh.
”Effect of sodium-glucose cotransporter 2 inhibitor on proximal
tubular function and injury in patients with type 2 diabetes: a
randomized controlled trial.” Clinical kidney journal 12.3 (2019):
326-332.
- Heyman, Samuel N., et al. ”Potential hypoxic renal injury in patients
with diabetes on SGLT2 inhibitors: caution regarding concomitant use
of NSAIDs and iodinated contrast media.” Diabetes Care 40.4 (2017):
e40-e41.
- Szalat, Auryan, et al. ”Can SGLT2 inhibitors cause acute renal
failure? Plausible role for altered glomerular hemodynamics and
medullary hypoxia.” Drug safety 41.3 (2018): 239-252.
- van Meer, Leonie, et al. ”Renal effects of antisense-mediated
inhibition of SGLT2.” Journal of Pharmacology and Experimental
Therapeutics 359.2 (2016): 280-289.
- Kadokura, Takeshi, et al. ”Ipragliflozin (ASP1941), a selective
sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates
urinary glucose excretion without inducing hypoglycemia in healthy
Japanese subjects.” Diabetology International 2.4 (2011): 172-182.
- Chaplin, Steve. ”SGLT2 inhibitors and risk of genitourinary
infections.” Prescriber 27.12 (2016): 26-30